Abstract: The disclosure relates to an artificial intelligence-based difficult airway evaluation method and device. The method includes the following steps: acquiring facial images of various postures; constructing a feature extraction network based on facial recognition, and extracting feature information of the facial images through the trained feature extraction network; and constructing a difficult airway classifier based on a machine learning algorithm, and performing difficult airway severity scoring on the extracted feature information of the facial images through the trained difficult airway classifier to obtain an evaluation result of a difficult airway. According to the present disclosure, early warning can be accurately provided for difficult airways in clinical anesthesia.

Abstract: The disclosure relates to a tracheal intubation positioning method and device based on deep learning, and a storage medium. The method includes: constructing a YOLOv3 network based on dilated convolution and feature map fusion, and extracting feature information of an image through the trained YOLOv3 network to acquire first target information; determining second target information by utilizing a vectorized positioning mode according to carbon dioxide concentration differences detected by sensors; and fusing the first target information and the second target information to acquire a final target position. According to the disclosure, the tracheal orifice and the esophageal orifice can be rapidly detected in real time.

Abstract: The present invention provides an odorant composition having good palatability allowing peoples to feel comfortable using a small number of chemical compounds. An odorant composition according to an embodiment of the present invention consists of: when the total mass of ingredients contained in the odorant composition is 100.0% by mass, 40.0% by mass or more and 97.5% by mass or less of an ingredient (A) composed of aldehydes; 1.0% by mass or more and 20.0% by mass or less of an ingredient (B) composed of a ketone(s); and the balance being an ingredient (C) composed of a chemical compound(s) other than the ingredient (A) and the ingredient (B). The aldehydes of the ingredient (A) are: an essential ingredient (A1) composed of nonanal; and an optional ingredient (A2) selected from the group consisting of decanal, heptanal, octanal, benzaldehyde, undecanal, hexanal, and combinations thereof.

Abstract: The present invention relates to the field of medical devices, and relates to an electrophysiological test method for an auditory brainstem implant (ABI) and a recording electrode used therein. According to the method of the present invention, there is no need to subcutaneously place an additional recording electrode for a patient, which simplifies preoperative preparation. Moreover, the method has advantages of a high signal-to-noise ratio, a fast response speed, a short recording time, and a large anti-interference ability, thus can effectively improve efficiency of intraoperative electrode test. The method is suitable for use in an auditory brainstem implantation surgery. Besides, the present invention enables the auditory brainstem implantation to be located more accurately, thereby expanding a scope of application.

Abstract: Disclosed by the present invention are an SIRT6 small-molecule allosteric activator and the application thereof and provided is an SIRT6 small-molecule allosteric activator that contains a derivative as shown in formula (1) or a pharmacologically acceptable salt thereof as the active ingredient. The SIRT6 small-molecule allosteric activator designed and synthesized in the present invention has high efficacy and low toxicity, may significantly activate SIRT6 activity during in vitro experiments, and has great importance in the development of pharmaceuticals for relevant diseases.

Abstract: [Problem to be Solved] Provided is a motile cell sorting device that can effectively sort motile cells, such as sperms, having excellent motility and morphology by performing image analysis when animal cells are sorted. [Means for Solution] The motile cell sorting device 1 comprises a storage unit 3, a first introduction unit (cell injection channel) 5, a first introduction control unit 7, a first holding unit (cell capture area) 9, a first derivation unit (cell collection channel) 11, a first derivation control unit 13, a collection unit (liquid storage) 15, a photographing unit 17, and a first controller 19.

Abstract: The present invention addresses the problem of providing a therapeutic agent for an abdominal aortic aneurysm, the therapeutic agent making drug therapy possible. The present invention provides a therapeutic agent for aortic aneurysm, the therapeutic agent having as active ingredients: (?)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these; and a statin.

Abstract: The present disclosure provides a bone reconstruction connection structure and method based on tenon-and-mortise fixation. The bone reconstruction connection structure based on tenon-and-mortise fixation includes at least two bone segments, and adjacent bone segments are detachably connected through a first connecting part and a second connecting part; the first connecting part includes a first tongue and a first shoulder, the first tongue protrudes from the first shoulder; the second connecting part includes a first slot and a first slot shoulder, and the first slot is retracted relative to the first slot shoulder, and the part of the first tongue protruding from the first shoulder matches the first slot. The bone reconstruction connection structure provided by the present disclosure is reinforced only through its own tenon-and-mortise structure, which can reduce the risk of infection, rejection and even secondary operation caused by implant fixation, and promote the healing of broken bone ends.

Abstract: The present invention provides a pharmaceutical composition containing an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor as an active ingredient, for use in treating HTLV-1-associated myelopathy. The present invention provides a pharmaceutical composition for use in treating HTLV-1-associated myelopathy, containing a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.

Abstract: A cell observation system observes a cell moving in a flow path with a fluid, and includes a first imaging apparatus, a second imaging apparatus, and a control device. The first imaging apparatus includes a first optical system and a first imaging element, and captures an image of the cell at a first position in a moving direction. The second imaging apparatus includes a second optical system, in which a focus is adjusted based on a focus adjustment signal, and a second imaging element, and captures an image of the cell at a second position downstream of the first position. The control device obtains a passing position of the cell in a cross section of the flow path based on the image obtained by the first imaging element, generates the focus adjustment signal, and provides the signal to the second optical system.

Abstract: The present invention is intended to provide a method for determining the prognosis of a hormone receptor-positive cancer (for example, an ER?-positive breast cancer, an ER?-positive endometrial cancer, etc.) or a method for assisting the determination of the prognosis, and a method for evaluating the sensitivity of the cancer to antihormone therapy or a method for assisting the evaluation of the sensitivity of the cancer to antihormone therapy. Specifically, the present invention relates to a method for determining the prognosis of a hormone receptor-positive cancer, or a method for assisting the determination of the prognosis, which comprises the following steps (a) and (b): (a) a step of detecting Fbxo22-positive cancer cells in a sample derived from the cancer tissues; and (b) a step of calculating the percentage of the Fbxo22-positive cancer cells to the cells present in the sample.

Abstract: A cell observation system observes a cell moving in a flow path with a fluid, and includes a first observation apparatus, a second observation apparatus, and a control device. The first observation apparatus includes an objective lens and a line camera. The second observation apparatus includes an objective lens and an area camera. The control device analyzes first imaging data output from the first observation apparatus to determine whether the cell satisfies a specific condition, instructs the area camera to output second imaging data of the cell determined to satisfy the specific condition, and analyzes the second imaging data output from the second observation apparatus to determine whether the cell is a specific cell.

Abstract: An instrument for fixedly transplanting a living body embryo into a uterus has an instrument, for transplanting the living body embryo into the uterus, which is to be inserted into a uterus and a magnetic embryo accommodation container holding instrument (transferred embryo fixing instrument) to be attached to the living body. The instrument for transplanting the living body embryo into the uterus has an embryo accommodation container having an embryo accommodation part having an embryo insertion portion communicating with outside and a magnetic material and a shaft-shaped container transfer tool for separably holding the embryo accommodation container at its distal end portion. The magnetic container holding instrument has an attaching part to be attached to an epidermis of the living body and a magnet capable of attracting the magnetic material of the embryo accommodation container thereto.

Abstract: The present invention provides a mitochondrial function-improving agent containing a lactic acid bacterium belonging to Lactobacillus farciminis or Pediococcus acidilactici, a culture of the lactic acid bacterium, or a culture supernatant of the lactic acid bacterium.

Abstract: The present invention addresses the problem of providing a therapeutic agent for abdominal aortic aneurysms, with which pharmacotherapy is possible. The present invention provides a therapeutic agent for an aortic aneurysm comprising, as an active component, (?)-6-[3-[3-cyclopropyl-3-[(1R,2R)-2-hydroxycyclohexyl]ureido]propoxy]-2(1H)-quinolinone or a salt thereof, or a solvate of these.

Abstract: Disclosed is a dental implant distractor, comprising an implant module and a traction module. The implant module comprises an implant, a sealing screw, and a base body. The traction module comprises a connecting screw rod, a traction screw rod, an inner sleeve, and an outer sleeve; the connecting screw rod is threadedly connected to the base body; the traction screw rod is located below the connecting screw rod; the inner sleeve is provided below the base body. This apparatus can automatically complete the installation of the base body and the sealing of the connecting screw rod after traction is completed; since the installation of the base body and the sealing do not need to be performed again, operation steps are simplified, the clinical operation difficulty is reduced, and the problem of slippage of an upper bone section to the original position is avoided.

Abstract: A method for producing a new deafness model animal and a new deafness model animal produced by the method, enabling research that can also be applied to clinical application to a human. The present invention provides a method for producing an acoustic trauma deafness model animal, the method including exposing a non-human primate animal to a sound having a frequency of 1 kHz to 32 kHz and a sound pressure level of 100 dB to 150 dB for 10 minutes to 360 minutes. In addition, the present invention provides an acoustic trauma deafness model animal provided by the method for producing an acoustic trauma deafness model animal.

Abstract: The present invention provides a therapeutic or prophylactic agent for HTLV-1-associated myelopathy (HAM), comprising an RGMa-inhibiting substance, and a method for treating HTLV-1-associated myelopathy (HAM), comprising administering a pharmacologically effective amount of an RGMa-inhibiting substance to an HAM patient in need thereof.

Abstract: The present invention provides use of salidroside and a derivative thereof in preparation of an inhibitor medicament for treating diseases, such as opthmalmic fibrosis, caused by abnormalities of extracellular matrix proteins. The present invention treats and prevents diseases associated with ocular fibrosis such as glaucoma, by inhibiting the expression of extracellular matrix proteins in the eye to prevent fibrosis. The present invention further provides use of an inhibitor medicament for treating and preventing diseases, such as opthmalmic fibrosis, caused by abnormalities of extracellular matrix proteins, the inhibitor medicament comprising an effective amount of salidroside and a derivative thereof as active ingredients.

Abstract: The present disclosure provides the use of a recombinant human secretory DDRGK1. Experiments demonstrate that the recombinant human secretory DDRGK1 prepared by the present disclosure can be used in the preparation of biological medicines for treating intervertebral disc degeneration, fractures or bone defects. The recombinant human secretory DDRGK1 of the present disclosure provides a promising direction for the treatment of bone related diseases and has obtained firm scientific evidence, thereby expanding the further application of recombinant human secretory DDRGK1 in clinical practice.